Skip to main content
SpringerLink
Log in

Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Pheochromocytoma and paraganglioma (PPGL) are rare neoplasms; about 10% are malignant. Literature regarding possible benefit from resection is extremely limited.

Methods

A 20 year review of all patients undergoing surgery for malignant PPGL at the Mayo Clinic Rochester Campus between 1994 and June 2014 was performed.

Results

We identified 34 patients undergoing surgery for malignant PPGL. Median follow up was 6 and 5 years survival was 90% (median 11 years). Complete resection (R0) was achieved in 14 patients (41%). Median disease-free survival was 4.6 years for patients with R0 resection (up to 12 years). Only eight patients (23%) were disease-free on last follow up. Elevated preoperative fractionated metanephrines or catecholamines were documented in 23 patients (68%); these normalized in 13 of 23 patients (56%) postoperatively—with symptom relief in 15 of 18 preoperatively symptomatic patients (79%). Among 23 patients with hormone-producing tumors, significant reduction in number of antihypertensive medications was also noted postoperatively; 11 patients have remained off all antihypertensives, 6 required 1 medication, 1 required 2, while 5 required full blockade with phenoxybenzamine and a beta-adrenergic blocker.

Conclusion

Surgery plays a significant role in the management of selected malignant PPGL. Resection can be effective in normalizing or significantly reducing levels of catecholamines and metanephrines, and can improve hormone-related symptoms and hypertension. Surgical resection, either complete or incomplete, is associated with durable survival despite a high rate of tumor recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58:802–4.

    CAS  PubMed  Google Scholar 

  2. Lee JA, Duh QY. Sporadic paraganglioma. World J Surg. 2008;32:683–7.

    Article  PubMed  Google Scholar 

  3. Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–64.

    Article  PubMed  Google Scholar 

  4. DeLellis RA. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.

    Google Scholar 

  5. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.

    Article  CAS  PubMed  Google Scholar 

  6. Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171:R111–22.

    Article  CAS  PubMed  Google Scholar 

  7. McBride JF, Atwell TD, Charboneau WJ, Young WF Jr, Wass TC, Callstrom MR. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol. 2011;22:1263–70.

    Article  PubMed  Google Scholar 

  8. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: implications for therapy. Ann N Y Acad Sci. 2006;1073:505–11.

    Article  CAS  PubMed  Google Scholar 

  9. Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas. Cancer. 2012;118:2804–12.

    Article  CAS  PubMed  Google Scholar 

  10. Ellis RJ, Patel D, Prodanov T, et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg. 2013;217:489–96.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92:3822–8.

    Article  CAS  PubMed  Google Scholar 

  12. Assadipour Y, Sadowski SM, Alimchandani M, et al. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery. In press.

  13. Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic, Rochester, MN, USA

    Veljko Strajina MD, Benzon M. Dy MD, David R. Farley MD, Melanie L. Richards MD, Travis J. McKenzie MD, Florencia G. Que MD, David M. Nagorney MD & Geoffrey B. Thompson MD

  2. Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    Keith C. Bible MD

  3. Division of Endocrinology, Metabolism, Nutrition and Diabetes, Mayo Clinic, Rochester, MN, USA

    William F. Young MD

Authors
  1. Veljko Strajina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benzon M. Dy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David R. Farley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melanie L. Richards MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Travis J. McKenzie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keith C. Bible MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Florencia G. Que MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David M. Nagorney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. William F. Young MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Geoffrey B. Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Veljko Strajina MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strajina, V., Dy, B.M., Farley, D.R. et al. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. Ann Surg Oncol 24, 1546–1550 (2017). https://doi.org/10.1245/s10434-016-5739-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5739-5

Keywords

Search

Navigation